Cost recovery initiative in Canada has "mixed" effect
This article was originally published in Clinica
Executive Summary
The cost recovery initiative (CRI) implemented by Canada's Therapeutic Products Programme (TPP) has had a mixed impact on the medical devices industry. This is the conclusion of an independent report, commissioned by Canada's drugs and devices regulator, the TPP, to evaluate how well the system is operating and whether changes should be implemented.